Pipeline
United Immunity's pipeline utilizes its Myeloid Targeting Platform™ with an initial focus on cancer and treatment resistant solid tumors. We would explore non-oncology pipeline through partnering.
Discovery
Lead
Preclinical
Ph 1
Ph 2
Ph 3
UI-102
Mode Of Action
Cold tumor to hot conversion
Molecular Target
TLR
Indication
HCC & other solid tumors
CAR-M
Mode Of Action
In-vivo CAR-M
Molecular Target
Not disclosed
Indication
Solid tumors
UI-201
Mode Of Action
Booster for TCR-T-cell therapy
Molecular Target
NY-ESO-1 antigen
Indication
Synovial sarcoma